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The ban on antimicrobial growth promoters and efforts to reduce therapeutic antibiotic 
usage has led to major problems of gastrointestinal dysbiosis in livestock production 
in Europe. Control of dysbiosis without the use of antibiotics requires a thorough 
understanding of the interaction between the microbiota and the host mucosa. The gut 
microbiota of the healthy chicken is highly diverse, producing various metabolic end 
products, including gases and fermentation acids. The distal gut knows an abundance 
of bacteria from within the Firmicutes Clostridium clusters IV and XIVa that produce 
butyric acid, which is one of the metabolites that are sensed by the host as a signal. 
The host responds by strengthening the epithelial barrier, reducing inflammation, and 
increasing the production of mucins and antimicrobial peptides. Stimulating the coloni-
zation and growth of butyrate-producing bacteria thus may help optimizing gut health. 
Various strategies are available to stimulate butyrate production in the distal gut. These 
include delivery of prebiotic substrates that are broken down by bacteria into smaller 
molecules which are then used by butyrate producers, a concept called cross-feeding. 
Xylo-oligosaccharides (XOS) are such compounds as they can be converted to lactate, 
which is further metabolized to butyrate. Probiotic lactic acid producers can be supplied 
to support the cross-feeding reactions. Direct feeding of butyrate-producing Clostridium 
cluster IV and XIVa strains are a future tool provided that large scale production of strictly 
anaerobic bacteria can be optimized. Current results of strategies that promote butyrate 
production in the gut are promising. Nevertheless, our current understanding of the 
intestinal ecosystem is still insufficient, and further research efforts are needed to fully 
exploit the capacity of these strategies.
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iNTRODUCTiON
For many years, broiler intestinal health was supported by the widespread use of antimicrobial 
growth promoters (AGPs). These AGPs are antibiotic substances that were added to the feed at 
subtherapeutic levels, leading to improved animal performance. In the European Union, the use 
of AGPs was banned in 2006 while the Center for Veterinary Medicine of the US Food and Drug 
December 2015 | Volume 2 | Article 752
Onrust et al. Optimizing Gut Health of Broilers
Frontiers in Veterinary Science | www.frontiersin.org
Administration, in 2012, wrote a “Guidance for Industry” docu-
ment recommending that antibiotics should only be used in case of 
specific diseases and not for growth promotion. The most impor-
tant reason for these precautionary measures was the likelihood 
that AGPs may increase antimicrobial resistance in bacteria, in 
some cases followed by introduction of these bacteria in humans 
(1). Most likely intestinal health problems in the chicken have 
been masked partly by the routine use of AGPs. Since the ban 
of AGPs in Europe alternative strategies for control of intestinal 
health have become a focus of research. These research efforts 
have revealed the complexity of the intestinal ecosystem. The gut 
indeed is an organ that contains many different cell types and 
exerts many different functions (2). In addition, the composition 
of the gut microbiota is diverse and varies depending on different 
factors, including the feed composition. The interaction between 
the host and the beneficial microbes in the intestine is mutual-
istic, as the host provides an anaerobic shelter and nutrients for 
the bacteria, which in turn provide enzymes that help digesting 
polysaccharides and other complex molecules (3). Nonetheless, 
the intestinal tract also contains facultative pathogenic microor-
ganisms, which may be harmful and even life-threatening to the 
host under certain conditions. The challenge for the intestinal 
immune system is thus to simultaneously create a firm barrier 
and a powerful defense against the pathogenic bacteria, while at 
the same time, foster the beneficial bacteria and create an open 
entrance for the nutrients. These apparently conflicting tasks 
are taken up by the intestinal mucosa forming the so-called 
intestinal barrier that receives signals from the intestinal bacteria 
(4). Microbial signals can originate from cell wall components, 
like lipopolysaccharides (LPS) and flagellin, DNA fragments, 
and metabolites such as short-chain fatty acids (SCFAs). Those 
signals can have proinflammatory or anti-inflammatory effects, 
depending on the signal (5). One important signal derived from 
the beneficial microbes is butyrate.
When considering signals derived from bacterial fermentation, 
butyric acid has been shown to be the main driving force toward 
an optimal gut health. The molecule exerts beneficial effects in 
the physiological concentration range (6, 7). Numerous butyrate 
products are available on the market in a wide range of formula-
tions. However, another possibility to increase butyric acid in the 
gut is by stimulating the endogenous production of butyrate by 
the gut microbiota. This review focuses on the methods on how to 
increase the endogenous production of butyrate in the intestinal 
tract of broilers in order to improve gut health.
ROLe OF THe iNTeSTiNAL BARRieR iN 
GUT HeALTH
The luminal side of the intestinal wall is lined with absorptive 
epithelial cells, needed for water and nutrient uptake, which 
form a semipermeable barrier between the outside world (the gut 
lumen) and the internal host tissues. This semipermeable barrier 
is not only formed by the cell membranes of the epithelial cells but 
also by tight junctions that connect neighboring epithelial cells 
(8). These connections are regulated at different levels (e.g., by 
cytokines). The permeability of the intestinal epithelial cell layer 
can be affected by epithelial cell death and also by luminal signals 
that increase the epithelial layer permeability by affecting the 
tight junctions and thus cause loss of integrity of this important 
barrier (4). This loss of integrity can have detrimental effects. 
First, it causes an efflux of host proteins (“leaky gut”) into the 
lumen and can cause luminal molecules, including toxins, and 
microorganisms, to reach the basal side of the epithelial layer. 
Through coevolution, the host has developed the capacity to 
become tolerant to most bacteria present in the lumen at the 
apical side of the epithelial cells. However, bacterial components 
that closely interact with epithelial cells from the basolateral side 
do trigger an inflammatory response. This is mediated by the 
binding of pathogen-associated molecular patterns, such as LPS 
and flagellin, to the so-called Toll-like receptors that trigger the 
cascade of proinflammatory signals (9). It is evident that the loss 
of intestinal epithelial integrity and its consequences will have an 
effect on animal performance.
In addition to the absorptive epithelial cells, other cell 
types are present in the lining of the gut wall. These include 
mucin-producing goblet cells and antimicrobial peptide (AMP)-
producing paneth cells in the crypts (10). Both cell types are very 
important in innate defenses. Enteroendocrine cells can also be 
found in the epithelial lining, secreting peptide hormones into 
the bloodstream. These peptide hormones have a variety of func-
tions, including effects on epithelial cell proliferation, inflamma-
tion, and consequently intestinal barrier integrity. One of these 
hormones is glucagon-like peptide-2 (GLP-2), a hormone that is 
important in maintaining epithelial integrity (11). The enteroen-
docrine cells are activated by various luminal signals, including 
bacterial signals (see below).
Underneath the epithelial lining, many other cell types are 
present which together form the lamina propria of the intesti-
nal mucosa. These cells include, among others, fibroblasts and 
endothelial cells. Immune cells are also present in the mucosa, 
both in organized lymphoid tissues and scattered between the 
other cells. All non-epithelial cell types are responsive to luminal 
triggers, whether transmitted by epithelial cell signals, including 
enteroendocrine cell hormones, or not, and thus can influence 
other cell types by themselves. Thus, intestinal barrier integrity, 
inflammation, and gut function are influenced by luminal signals, 
many of which are produced by the microbiota (12). The compo-
sition of the microbiota and the metabolites the bacteria produce 
are hence crucial for gut health.
eFFeCTS OF BUTYRATe
One of the major terminal metabolites of intestinal bacteria is 
butyrate. The effects of butyrate on intestinal health have already 
been described in detail in many reports (6, 13). The main targets 
of butyrate are briefly described in the following paragraph. 
Supplementation of butyrate in the feed can beneficially influ-
ence growth performance and intestinal villus structure in broiler 
chickens (14). Presence of butyrate in the intestine plays a role 
in the control of pathogens such as Salmonella Enteritidis and 
Clostridium perfringens. Reduction of Salmonella enterica sero-
var Enteritidis colonization and shedding in chickens has been 
reported (15, 16), as well as a decrease of necrotic lesions induced 
December 2015 | Volume 2 | Article 753
Onrust et al. Optimizing Gut Health of Broilers
Frontiers in Veterinary Science | www.frontiersin.org
by C. perfringens in the small intestine (17). In addition to the 
role of butyrate in growth performance and pathogen control, 
butyrate also has anti-inflammatory properties. One of the 
mechanisms is inhibition of nuclear factor-kappa B activation, 
resulting in decreased expression of proinflammatory cytokines 
(18, 19). As described above, the intestinal barrier plays an 
important role in maintaining intestinal health. Butyrate has an 
effect on several components of this barrier (13, 20), such as the 
tight junctions (21). Butyrate upregulates AMP-activated protein 
kinase, which regulates the assembly of tight junctions (22). The 
mucin-producing goblet cells in the small intestine and distal gas-
trointestinal tract are also influenced by the presence of butyrate 
(23, 24). Butyrate-induced expression of MUC2 genes results in 
secretion of mucin, a glycoprotein, which forms a protective layer 
on the enterocytes (23, 25). AMP-producing paneth cells in the 
crypts are another cell type influenced by butyrate. Expression of 
AMPs, such as cathelicidins and defensins, is upregulated upon 
supplementation of butyric acid (26, 27). Finally, it is assumed 
that butyrate affects enteroendocrine L-cells secreting GLP-2 
(28). Beneficial effects of GLP-2 on general gut health, such as the 
stimulation of intestinal crypt cell proliferation and the reduction 
of apoptosis in the crypt compartment, have been described for 
several animal species (29, 30). Information about the function 
of GLP-2 in chickens is scarce. Honda et al. (31) reported sup-
pressed feed intake after intracerebroventricular administration 
of GLP-2 in chickens, which suggests that GLP-2 plays a role in 
regulating appetite (31). Daily intraperitoneal injection of GLP-2 
in healthy broiler chickens improves absorptive function of the 
small intestine and has a positive effect on growth performance 
(32). GLP-2 receptors are thought to be present in chicken 
proventriculus, duodenum, jejunum, ileum, cecum, and colon, as 
detected by PCR (33). L-cells containing GLP-2 are mainly found 
in the crypts of the distal ileum and the proximal jejunum (34). 
This information could prove useful in unraveling the functions 
of GLP-2 in birds and in finding out which physiological triggers 
lead to secretion of the hormone (35). In humans, it is reported 
that butyrate enhances GLP-2 secretion and increases GLP-2 
plasma concentration (35, 36). However, studies in chickens are 
lacking, and further research is necessary to yield conclusive 
information about the effect of butyrate on the release of GLP-2 
in chickens.
THe iNTeSTiNAL MiCROBiOTA wiTH 
FOCUS ON eNDOGeNOUS BUTYRATe 
PRODUCTiON
The composition of the microbiota in the gut of chickens depends 
on the age and the gastrointestinal segment, i.e., there is both a 
temporal as well as a spatial variation (37). In general, the diversity 
of the microbiota increases with age. The composition of micro-
biota differs between the different segments of the chicken gut. 
In general, low numbers of bacteria are found in the proximal 
parts of the gut (stomach, duodenum, jejunum, <103  cfu/g 
content), while the numbers increase toward the distal ileum and 
ceca, the latter harboring more than 1010 bacteria/g of content. 
In addition, the diversity increases significantly toward the distal 
gut. While only a limited diversity can be observed in the small 
intestine, with lactobacilli often dominant, the ceca harbor a large 
number of different bacterial groups (38). The cecal ecosystem of 
healthy subjects is dominated by bacteria belonging to the phyla 
Bacteroidetes and Firmicutes, together comprising more than 80% 
of the microbiota. The former contains many polysaccharide-
degrading bacterial species, while the latter contains a variety of 
bacterial families, of which the Ruminococcaceae (Clostridium 
cluster IV) and Lachnospiraceae (Clostridium cluster XIVa) 
families are capable of fermenting various substrates to butyrate. 
The bacterial community has the genetic potential to carry out 
an enormous number of physiological functions (37). They can 
play an important role in both immune and digestive functions. 
Commensal bacteria can exert anti-inflammatory properties by 
producing SCFA (see below). Moreover, the mucosal architecture, 
mucus composition, and production can be affected by the pres-
ence of the gastrointestinal bacteria (39). The number of microbial 
genes in the gut of a chicken exceeds the number of chicken genes. 
Together these form a so-called “hologenome” (40).
Butyrate-Producing Bacteria and Bacteria 
That Promote/inhibit Butyrate Production
Butyrate-Producing Bacteria
While a large variety of bacteria can produce acetic acid, the 
most important butyric acid-producing bacteria belong to a 
limited number of families, including the Ruminococcaceae and 
Lachnospiraceae (41). These families contain strictly anaerobic 
bacteria that are highly abundant in the gut of healthy chickens, as 
well as mammals. Other Clostridium clusters, including clusters I 
and XVI, contain butyrate producers, but the level of butyrate pro-
duced is much lower in comparison with strains from cluster IV 
and XIVa (42, 43). Individual butyrate-producing strains isolated 
from chicken ceca have been characterized (44, 45). In 2011, a first 
study specifically investigated the diversity of butyrate-producing 
bacteria from chicken ceca. 16S rRNA gene sequence analysis of 
isolates revealed members of Clostridium clusters IV, XIVa, XIVb, 
and XVI (42). When butyrate-producing bacteria are present in 
a sufficiently high concentration, the epithelial barrier integrity 
will be stronger, the epithelial cells will proliferate more and thus 
the villi will be longer. Moreover, inflammatory reactions will 
be reduced, while the stimulation of regulatory T-lymphocytes 
will yield a state of tolerance toward non-harmful bacteria (46). 
Butyrate is mainly synthesized via the reductive acetyl-coenzyme 
A pathway (47). Via a four-step pathway, acetyl-CoA is converted 
to the intermediate butyryl-CoA and further to butyrate. The 
final step or actual butyrate formation in its synthesis is mostly 
catalyzed by butyryl-CoA:acetate CoA-transferase and is used 
by several families of the healthy gut microbiota, dominated by 
Lachnospiraceae and Ruminococcaceae (48, 49). Another, but 
less frequently used, enzyme in the final step is butyrate kinase 
that produces butyrate from butyrylphosphate that is derived 
after phosphorylation of butyryl-CoA (7). Recently, it has been 
hypothesized that a propionate CoA transferase related to the 
enzyme of Clostridium propionicum is responsible for butyrate 
formation in members of the family Erysipelotrichaceae (42). 
In addition, three other butyrate-producing pathways using 
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amino acids as major substrates are known. These pathways, only 
present in 20% of potential butyrate producers, are the lysine, 
4-aminobutyrate, and glutarate pathways (47).
Other Microorganisms That May Interact with 
Butyrate Production
The variety of metabolic functions of the intestinal microbiome 
encompasses degradation of complex substrates (polysaccha-
rides, proteins, and fat), fermentation of substrates to yield acidic 
compounds, immunomodulation, communication with other 
bacteria, and much more. To break down complex substrates, 
the bacteria form a food web, with different species and strains 
involved in different steps of the substrate utilization process 
(50). In a simplified model, complex substrates such as polysac-
charides, including arabinoxylans, pectins, and cellulose, are con-
verted to oligosaccharides by specific bacterial populations such 
as lactobacilli and some Bacteroides species, among others. These 
oligosaccharides [e.g., arabinoxylan-oligosaccharides (AXOS)] 
are then used by other bacterial groups to produce lactic acid, 
hydrogen, and SCFAs such as acetic, propionic, and butyric acid 
(41). The system in which bacteria convert substrates to products 
that are converted by other bacteria is called cross-feeding. 
This is an important mechanism, clearly showing the need of 
a diverse bacterial community, in order to be able to degrade 
substrates (51, 52). In case of dysbiosis, an unfavorable shift in 
the composition of the microbiota occurs, leading to deficiencies 
in certain crucial steps in certain pathways, yielding changes 
in the bacterial metabolites produced in the gut (53). Bacteria 
that promote butyrate production through the production of 
intermediate metabolites, as well as bacteria that inhibit butyrate 
production by competition for substrates can be present in the 
gut. For example, the underlying mechanism by which lactic 
acid bacteria (LABs) can be beneficial can be explained by the 
effects of butyrate, considering that the lactic acid produced by 
these bacteria is then further consumed by Clostridium cluster 
XIV strains to produce butyrate (48). Lactic acid is toxic by itself 
when present in high concentrations and only has a benefit when 
it is converted (54). Sulfate-reducing bacteria (SRBs) compete for 
lactate with butyrate-producing bacteria from Clostridium cluster 
XIVa, with the outcome of this competition being a crucial factor 
for gut health. Apart from this, SRBs also have to compete for 
hydrogen with hydrogenotrophic acetogenic and methanogenic 
bacteria (55). They produce hydrogen sulfide as a terminal 
metabolite. Hydrogen sulfide, with proven cell death-inducing 
effects on intestinal epithelial cells, is a clearly toxic metabolite 
(56). One can thus conclude that a complex interaction between 
different bacterial populations for specific substrates exists, and 
the outcome of this interaction can drive the microbiota either 
to produce beneficial metabolites which promote gut health, or 
toward production of toxic metabolites.
TOOLS TO STiMULATe eNDOGeNOUS 
BUTYRATe PRODUCTiON
Probiotics
The term probiotics was first defined by FOA/WHO in 2001, and 
at the end of 2013, the definition was worded more grammatically 
correct as “live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host” (57). 
The majority of bacterial probiotics consist of LABs, mainly 
from the Lactobacillus, Bifidobacterium, Enterococcus, and 
Streptococcus genera (58, 59). As discussed above, lactic acid can 
be consumed by butyrate-producing bacteria to produce butyrate 
(48). Different types of products are currently available on the 
market. Beside single-strains, multi-strain products are available, 
as well as competitive exclusion (CE) products, which contain 
a freeze-dried mixture of gut content. The main purpose of CE 
products is replacing the natural route of microbiota succession, 
while probiotics enhance the functions of existing microbiota. 
Besides, only defined CE products can be registered for which 
the identities of the bacteria in the mixture are known to be safe 
for chickens and humans (60).
Reports of the effect of probiotics on animal performance have 
been published (61, 62), and studies on the beneficial effect on 
pathogen colonization and disease reduction are widely available 
(63–65). However, positive effects are not observed in all studies. 
One of the reasons for the inconsistency of observed beneficial 
effects may be that success depends partly on the conditions of 
the study, i.e., feed formulae and feed ingredients, management 
factors, and presence or absence of stress factors and challenge 
conditions. Indeed, unpublished data from our laboratory show 
that the efficacy of probiotics is highly dependent on the model 
used. However, based on the above described data, attempts could 
be made to develop probiotics that stimulate butyrate production 
in the intestinal tract, either directly or through cross-feeding.
Butyrate-Producing Bacteria as Probiotic Strains
Most butyrate-producing bacteria belong to the Clostridium 
clusters IV and XIVa (66, 67) and play an important role in 
maintaining a healthy gut primarily through production of 
butyrate (7). These bacteria are less abundant in the gut of 
people suffering from inflammatory bowel disease (IBD) 
as compared to healthy persons (68). More specifically, 
Butyricicoccus  pullicaecorum and Faecalibacterium prausnitzii, 
species belonging to Clostridium cluster IV, have been shown to 
be less abundant in the gut of IBD patients (68, 69). Thus, oral 
administration of these strains as probiotics might counteract 
IBD inflammation. At the moment, no specific studies are 
available in literature that show beneficial effects of butyrate-
producing bacteria from Clostridium clusters IV and XIVa as 
probiotic candidates in poultry. However, Clostridium butyri-
cum from Clostridium cluster I, administered as a component 
of a tri-strain probiotic, significantly improved body weight 
gain and reduced feed conversion rate in broiler chickens (70). 
Similar results have been reported with supplementation of C. 
butyricum in the feed as single strain probiotic (71).
A major problem with the production of butyrate-producing 
bacteria as probiotic is the cultivation, as these microorganisms 
require strict anaerobic conditions (72). Another issue is that 
most poultry feed is pelleted, and probiotic strains are exposed to 
high temperatures during this process. Thus, ideally the probiotic 
strains should be heat-stable, for example, through spore forma-
tion (73). Unfortunately, most butyrate-producing bacteria seem 
to lack this characteristic.
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Other Microorganisms as Probiotic Strains 
Increasing Butyrate Concentration
Instead of direct administration of butyrate-producing bacteria 
to the bird, attempts could be made to use strains that stimulate 
butyrate production by Clostridium cluster IV and XIVa strains. 
The Clostridium cluster XIVa strains consume lactic acid to 
produce butyric acid. Therefore, LABs could be useful probiotics 
for their property of indirect stimulation of butyrate production. 
This cross-feeding mechanism may explain the beneficial effects 
of lactobacilli and bifidobacteria (70, 74). Addition of lactoba-
cilli in an in vitro fermentation system of cecal broiler content 
increases butyrate concentration (75). This suggests that lactoba-
cilli, as probiotic bacteria, stimulate butyrate-producing bacteria 
in the chicken cecum. These effects are, however, hitherto not 
investigated in vivo in chickens.
Prebiotics
The definition of prebiotics as proposed by Gibson et al. (76) is 
“Selectively fermented ingredients that allow specific changes, 
both in the composition and/or activity of the gastrointestinal 
microflora that confer benefits upon host wellbeing and health” 
(76). Several prebiotics induce beneficial effects on broiler 
performance and pathogen control (77, 78). Most published 
studies involve oligosaccharides, such as fructo-oligosaccha-
rides (FOS), galacto-oligosaccharides (GOS), arabinoxylo-
oligosaccharides (AXOS), xylo-oligosaccharides (XOS), and 
raffinose family oligosaccharides (RFOs) (79). Prebiotics are 
complex molecules because of the chain length, the nature 
of the sugar bonds, and the nature of the side chains on the 
saccharides. These characteristics can affect their function as 
prebiotic (80). Prebiotics need to be converted into metabolites 
by the microbiota in the gut. Because they are saccharides, their 
end products will be SCFAs, lactate, and gases, and thus the 
beneficial effect can theoretically be evaluated or predicted by 
analyzing these metabolites.
Prebiotics Used By Butyrate-Producing Bacteria and 
Other Microorganisms
Prebiotics that stimulate colonization and activity of butyrate-
producing Clostridium cluster IV and XIVa populations are 
considered to be beneficial. For example, our group showed that 
XOS supplementation to a broiler diet increases the number of 
lactobacilli and Clostridium cluster XIVa strains in the distal gut, 
thereby stimulating the cross-feeding between both groups, so 
that lactate is converted into butyrate (78). Different studies report 
improved growth performance and an increase of Lactobacillus 
and Bifidobacterium bacteria in the gut of broilers after admin-
istration of oligosaccharides (81–83). After supplementation 
of AXOS in the diet, a decrease of Salmonella Enteritidis and 
improved feed conversion rate is reported in poultry (44, 84). 
Contradictory results have been published with FOS supplemen-
tation in broilers. Several studies report a decrease of pathogen 
colonization, i.e., Salmonella, C. perfringens, and Escherichia 
coli, in the cecum of broilers (81, 85, 86), and an increase of 
Bifidobacterium spp. and Lactobacillus spp. (81). Other studies 
in broilers report no effect at all (87, 88). These discrepancies 
could be explained by differences in age, diet composition, and 
concentration of FOS in the diet. As discussed above, it can be 
hypothesized that the observed beneficial effects are at least partly 
due to the bacteria supporting the cross-feeding leading toward 
production of butyrate.
CONCLUSiON
A large number of experimental and field trials in broilers have 
already been carried out, using a variety of feed additives. The 
most commonly measured outcome parameter is performance. 
Some studies were also done to determine the effect on pathogen 
colonization. The approach was mostly empirical and the products 
were therefore mainly developed without a clear understanding 
of the mode of action underlying the hoped-for beneficial effects. 
The only way to develop products with an enhanced activity as 
compared to the already existing products will be based on a thor-
ough understanding of the intestinal ecosystem. Identification 
of the microbiota components that are crucial to gut health is 
ongoing and forms an essential part of the proper development 
of additives that support gut health (67). This needs to be done 
in both ways, i.e., identifying both the beneficial microbes as 
well as the harmful ones. Current knowledge indicates that 
butyrate-producing bacteria and their metabolite butyrate 
improve gut health in the physiological range (6). The amount of 
butyrate produced by the microbes in the lower intestinal tracts 
is impressive, considering that more than 50% of the microbiome 
is composed of butyrate producers (7). Deficiencies in butyrate 
production by the microbiota for whatever reason always seem 
to lead to inflammation in the intestinal tract (13). Providing a 
butyrate supplement in the feed only gives a partial answer to the 
problem, as the amount that can be added to the feed is limited. 
Thus, there is ample reason to try and stimulate endogenous 
butyrate production. This can be achieved by using feed additives, 
i.e., prebiotics that support the proliferation and the metabolic 
activities of the butyrate producers. Another possible strategy to 
stimulate endogenous butyrate production is by direct feeding of 
butyrate-producing bacteria. However, most probably a range of 
other metabolites exists with unknown mechanisms and influ-
ences on gut health. There is a need to investigate the specific 
effects of the different bacteria and metabolites that are found to 
play a role in gut health. Bacterial culturing is a crucial tool to 
foster our understanding of the intestinal ecosystem and essential 
in studying the effect of a specific species or strain on gut health 
parameters (2). Only a small minority of the microbial species 
residing in the gut has ever been cultured, and therefore isolation 
and characterization of new bacterial species from the gut will 
yield useful information (89).
Finally, the feed–microbiota–host interactions are extremely 
complex, but expertise on how to steer this interaction is grow-
ing rapidly. One way is to increase the abundance of butyrate-
producing bacteria from Clostridium cluster IV and XIVa. In 
the future, many more health promoting as well as harmful 
bacterial groups and metabolites will doubtlessly be discovered. 
This will further contribute to optimizing gut health and animal 
performance.
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